Israeli drug prevents 100% of COVID patients from deteriorating in trial
All 18 hospitalized individuals administered the treatment developed by Israeli biotech company Amorphical in a phase II trial recovered and were discharged in a few days.
Medical personnel work at the Intensive Care Unit (ICU) for COVID-19 patients at the Emile Muller GHRMSA hospital in Mulhouse, France, December 16, 2021(photo credit: REUTERS/YVES HERMAN/FILE PHOTO)ByROSSELLA TERCATINUpdated:
